How it All Plays Out: Complementary Research on China Cord Blood, Biolase, Cara Therapeutics, Tonix, and Enzo Biochem
NEW YORK, April 24, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including China Cord Blood Corporation (NYSE: CO), Biolase, Inc. (NASDAQ: BIOL), Cara Therapeutics, Inc. (NASDAQ: CARA), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), and Enzo Biochem, Inc. (NYSE: ENZ). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CO Research Report: ( http://get.analystsreview.com/pdf/?c=China%20Cord%20Blood&d=24-Apr-2015&s=CO ),
BIOL Research Report: ( http://get.analystsreview.com/pdf/?c=Biolase&d=24-Apr-2015&s=BIOL ),
CARA Research Report: (http://get.analystsreview.com/pdf/?c=Cara%20Therapeutics&d=24-Apr-2015&s=CARA ),
TNXP Research Report: ( http://get.analystsreview.com/pdf/?c=Tonix&d=24-Apr-2015&s=TNXP ),
ENZ Research Report: ( http://get.analystsreview.com/pdf/?c=Enzo%20Biochem&d=24-Apr-2015&s=ENZ ).
============
--
Analyst Update: Financial Results, Scheduled Conference Calls, and Regulatory Approvals
Reviewed by: Rohit Tuli, CFA®
U.S. stocks continued to surge to record highs on Thursday as the Nasdaq Composite closed at its highest level ever, supported by better than expected corporate earnings. The Nasdaq Composite gained 0.41%, or 20.89 points to close at an all-time record high of 5056.06. The S&P 500 advanced 0.24%, or 4.97 points to 2112.93, and the Dow Jones Industrial Average closed the session at 18,058.69, up 0.11% or 20.42 points. European stocks mostly closed lower on Thursday as investors remained vigil on Greece's debt turmoil and cash crunch situation. Germany's DAX 30 and France's CAC 40 dropped 1.21% and 0.62%, respectively, while London's FTSE 100 gained modestly by 0.3% on Thursday. Meanwhile, Asian stock markets mostly advanced on Thursday as the Shanghai Composite and Japan's Nikkei both closed higher.
China Cord Blood Corporation (China Cord Blood) in its preliminary Q3 FY 2015 financial results informed that its revenues increased to RMB166.7 million ($26.9 million) from RMB150.6 million in the prior year period. Net income attributable to its shareholders was at RMB33.4 million ($5.4 million), compared to RMB34.6 million in the prior year period.
On April 23, 2015, Biolase, Inc. (Biolase), the global leader in dental lasers informed that it has scheduled to release its Q1 2015 financial results on Thursday, April 30, 2015, at approximately 4:05 p.m. ET.
On March 26, 2015, Cara Therapeutics, Inc. (Cara Therapeutics) announced its Q4 2014 and full- year 2014 financial results. For the quarter, total revenue stood at $914,000 versus $973,000 in Q4 2013. The Company reported net loss available to common stockholders of $4.2 million, or $0.18 per diluted share, for Q4 2014, versus net loss available to common stockholders of $2.1 million, or $0.49 per diluted share in Q4 2013.
Tonix Pharmaceuticals Holding Corp. (Tonix) in its Q4 2014 earnings release reported a net loss of $9.0 million, or $0.83 per diluted share, compared to a net loss of $3.7 million, or $0.74 per diluted share, for Q4 2013.
On March 13, 2015, Enzo Biochem, Inc. (Enzo) announced that the New York State Department of Health has granted conditional approval for its Enzo Clinical Labs' use of the FlowScript™ assay in detection of mRNA from HPV oncogenes, E6 and E7.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article